Home Contact Us Sitemap
Kopran Limited
Products
Active Pharmaceutical Ingredients
Bulk Drugs
 
Untitled Document

Products

API’s

Category

Specifications

Regulatory Status

Atenolol

Anti-Hypertensive

IP/BP/EP/USP

CEP, EU GMP

Amlodipine Besylate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Metoprolol Succinate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Metoprolol Tartrate

Anti-Hypertensive

IP/BP/EP/USP

DMF Available

Roxithromycin

Macrolides

IP/BP/EP

CEP, KFDA

Azithromycin

Macrolides

IP/BP/EP/USP

CEP

Clarithromycin Granules 27.5%

Macrolides

In-House

DMF Available

Clarithromycin Granules 33%

Macrolides

In-House

 

Clarithromycin Granules 43%

Macrolides

In-House

DMF Available

Pregabalin

Neuromodulator

IP/EP/In-House

EU DMF available and CEP applied

Ceftriaxone Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefotaxime Sodium

Sterile Cephalosporins

IP/BP/EP/USP

DMF Available

Cefepime (with L-Arginine) for Injection

Sterile Cephalosporins

IP/USP

 

Meropenem (with Sodium Carbonate) for Injection

Carbapenems

IP/USP

DMF Available

Doripenem

Carbapenems

In-House

DMF Available

Biapenem

Carbapenems

In-House

DMF Available

Lymecycline

Anti-Acne,

Anti-Infective

EP

 

Nitroxoline

Urological

In-House

 

Ticagrelor

Anti-Thrombotic

IP / In-House

 

 


Pellets


Pellets

Category

Duloxetine Pellets 17%, 21.5%

Anti-Depressent

Esomeprazole Pellets 8.5%, 15%, 22%

Anti-Ulcerant

Venlafaxine Pellets 33%, 42.7%

Anti-Ulcerant


Products under development

API's

Category

R&D Sample availability

R&D Tech pack availability

Specifications

Apixaban

Anti-Thrombotic

Apr.2018

May.2018

In-House

Dabigatran Etexilate Mesylate

Anti-Thrombotic

May.2018

June.2018

In-House

Rivaroxaban

Anti-Thrombotic

Apr.2018

May.2018

In-House

Canagliflozin

Anti-Diabetic

Jul.2018

Aug.2018

In-House

Dapagliflozin

Anti-Diabetic

Sep.2018

Oct.2018

In-House

Empagliflozin

Anti-Diabetic

Nov.2018

Dec.2018

In-House

Chlorthalidone

Anti-Hypertensive

Sep.2018

Oct.2018

EP/USP

Hydroxychloroquine Sulphate

Anti-Malarial

Sep.2018

Oct.2018

USP

Tebipenem

Carbapenems

Apr.2018

May.2018

In-House

Imipenem  (Non-Sterile)

Carbapenems

May.2018

Jun.2018

USP

Ertapenem

Carbapenems

May.2018

Jun.2018

In-House

Faropenem

Carbapenems

Aug.2018

Sep.2018

In-House

Citicoline Sodium

Central Stimulant

May.2018

Jun.2018

In-House

 

Note :
Products will not be offered for sale in countries where valid Patents are in force.
It is the responsibility of the buyer to comply with the above.
For more information on APIs,  send an E-mail to : api@kopran.com
Home | Careers | Legal Disclaimer | Sitemap